Imperial Recognized as 2025 Best & Brightest Company to Work For in West Michigan! Learn More

Imperial Clinical Research Services Blog
  • Services
    • What We Do
    • Study and Site Print Materials
    • Clinical Trial Translation Management
    • Ancillary Trial Supplies and Equipment
    • Clinical Trial Patient Engagement
    • CRO-Centered Services
    • A La Carte Services
  • Resources
    • Ebooks
    • Case Studies & Fact Sheets
  • About
    • About Us
    • News
    • Events
    • Corporate Responsibility
  • Contact
    • Contact Imperial
    • Career Opportunities
  • Blog
  • Marketplace
  • Services
    • What We Do
    • Study and Site Print Materials
    • Clinical Trial Translation Management
    • Ancillary Trial Supplies and Equipment
    • Clinical Trial Patient Engagement
    • CRO-Centered Services
    • A La Carte Services
  • Resources
    • Ebooks
    • Case Studies & Fact Sheets
  • About
    • About Us
    • News
    • Events
    • Corporate Responsibility
  • Contact
    • Contact Imperial
    • Career Opportunities
  • Blog
  • Marketplace
Tag:

Risk Share

    Business InsightsPatient Recruitment and Retention

    Risk-Share Pitfalls: What to Look For

    by Melynda Geurts March 28, 2014
    written by Melynda Geurts

    Risk share by definition means that each party puts something at risk. Oftentimes in the life-science industry there is one-sided risk and not a lot of sharing. Many companies try and establish standardized processes for risk sharing just to find out that study-specific nuances prevent this from happening.

    Each study is truly unique in its design and the way it’s operationalized at the site level. Some studies lend themselves to risk share being evaluated on screened patients, while others lend themselves to a referral evaluation. A risk-share program based on randomized patients is very challenging and opens a lot of speculation. It is the research center’s responsibility to enroll a patient into a trial, not the recruitment vendor’s responsibility.

    When developing a risk-share program, consider mutual key performance indicators (KPIs). Ensure all required parties agree to these KPIs being listed in the contract. And be aware of evaluation challenges that may be unforeseen. For example, determining the appropriate tracking mechanism can be difficult.

    In a recent global relapsing-remitting multiple sclerosis study, we decided to use the established IVR system to track during the screening visit how an individual learned about the study. We agreed on the prompt definitions describing the various sources of referral. Training was conducted with the sites on how to mark the appropriate prompts within the system.

    Our risk share was based on screened patients who were attributable to Imperial. At an interim evaluation of the data, we had achieved 30 percent of our target. But upon further analysis, we noticed that some of the recorded prompts were incorrect because, for example, we hadn’t initiated a specific service yet. Therefore, an unplanned detailed analysis had to take place, resulting in us only achieving 21 percent of our goal, which represented a 46 percent decrease from the initial analysis.

    These findings resulted in several observations: (1) despite proper training there still was inaccurate reporting in the IVR system; (2) we needed to reassess how to accurately track the impact of our strategies; and (3) we had to revise the existing risk-share agreement.

    So just keep in mind that desired risk-share agreements may be limited or become null and void if KPIs are not met.

    March 28, 2014 0 comment
    0 FacebookTwitterLinkedinEmail

Welcome

Welcome

The Imperial blog features content of interest to life-science professionals, with a special focus on clinical trials. We hope you will enjoy our experts’ perspectives, and invite you to join the conversation by leaving your comments. Please let us know of any additional topics you would like to see covered here.

Signup for our Blog Subscription

Signup for our Blog Subscription

Keep in touch

Twitter Linkedin Youtube Email RSS

Popular Posts

  • 1

    See Do Get

    August 12, 2014
  • 2

    Clinical Research Phases and the Path to Drug Approval

    August 8, 2023
  • 3

    Google Translate: The Unwitting Confidentiality Flaw

    April 15, 2020
  • 4

    25 Reasons People Aren’t Enrolling in Your Clinical Trial

    October 29, 2015
  • 5

    Clinical Trial Supply Chains: The Key to Avoiding Disruptions

    May 10, 2022

Categories

  • Ancillary Trial Supplies and Equipment (28)
  • Business Insights (125)
  • Clinical Trial Writing and Design (36)
  • Life-Science Events (53)
  • Patient Engagement (32)
  • Patient Recruitment and Retention (94)
  • Site Materials & Logistics (45)
  • Study Site Management (21)
  • Translation of Study Materials (17)
Imperial Clinical Research Services Blog

Imperial is a global leader in clinical trial solutions and support, specializing in study and site print materials, ancillary trial supplies and equipment, clinical trial translation management, and clinical trial patient engagement.

Imperial CRS Corporate Headquarters
3100 Walkent Drive NW
Grand Rapids, MI 49544

Contact

connect@imperialcrs.com

800.777.2591

020 3887 3437

Employment

Social

We Run on EOS - Entrepreneurial Operating SystemEcovadis Sustainability Rating January 2024West Michigan's Best and Brightest Companies to Work For Winner 2025The Best and Brightest Companies to Work For Logo
© Imperial CRS, LLC | Privacy Policy
Signup for our Blog Subscription

Subscribe to our blog and get the latest updates, insights, and industry trends delivered straight to your inbox. Stay informed and never miss a post.